Vaxcyte, Inc.

Engineering broad-spectrum conjugate vaccines, led by a 31-valent pneumococcal conjugate vaccine candidate.

Back to company catalog

Infectious disease / vaccines · Conjugate vaccines · Late clinical (Phase 3)

Compare report options